[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566236":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":10,"responsibleParty":29,"collaborators":10,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":10,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":45,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":51,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":10},{"fullName":5,"class":6},"Shanghai Pulmonary Hospital, Shanghai, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"group 1",null,"Baseline characteristics and information during loratinib treatment were collected",[13],"Other: Group 1",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Group 1","without Intervention",[9],[20],{"name":21,"affiliation":5,"role":22},"Chunxia Su, Doctor","STUDY_CHAIR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Li Wang, Doctor","CONTACT","18170211997","leewang8023@163.com",{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Chunxia Su","Director of Clinical Research Center, Shanghai Pulmonary Hospital","100566236","the-incidence-and-risk-factors-of-central-nervous-system-adverse-events-of-lorlatinib-in-patients-with-alk-positive-advanced-non-small-cell-lung-cancer-a-real-world-study-100566236",false,"NCT06652555","The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study","The CNS AE of Lorlatinib in Patients with ALK-positive Advanced NSCLC","Inclusion Criteria:\n\n* Patients with locally advanced (stage IIIb\u002FIIIc), metastatic, or recurrent (stage IV) NSCLC confirmed by histology or cytology, who are not eligible for curative surgery and cannot undergo definitive radiotherapy\u002Fchemotherapy, according to the 8th edition of the TNM staging classification by the International Association for the Study of Lung Cancer and the American Joint Committee on Cancer;\n* ALK-positive and the test results were based on RT-PCR \u002FFISH \u002FIHC \u002FNGS methods in the laboratory department or testing institution of the hospital\n* receiving targeted therapy with Lorlatinib\n* age ≥18 years old\n* follow-up after receipt of Lorlatinib\n* voluntarily participate in the study and sign informed consent\n\nExclusion Criteria:\n\n* evidence of any severe or uncontrolled systemic illness, including uncontrolled hypertension and active bleeding, active infections including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).\n* combined with other malignant tumors and received other anti-tumor therapy during the treatment of Lorlatinib","ALL","18 Years",{"count":43,"type":44},100,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this study is to investigate the incidence and risk factors of central nervous system adverse events of Lorlatinib in patients with ALK-positive advanced non-small cell lung cancer.",[49,50],"ALK","NSCLC",[49,50],"NOT_YET_RECRUITING","2024-10-19",{"date":55,"type":56},"2024-10-22","ACTUAL",{"date":58,"type":44},"2024-10-30",{"date":60,"type":44},"2027-09-29",{"name":5,"class":6}]